Research Website
https://www.chem.purdue.edu/low/
Keywords
Pituitary Adenylate Cyclase-Activating Polypeptide, Vasoactive intestinal peptide, bone fracture, targeted therapeutics, neuropeptide
Presentation Type
Poster
Research Abstract
In patients over the age of 65 especially, bone fractures represent a significant disease burden. Non-invasive drug therapies are not available for bone fractures which represents a problem for this population. Vasoactive intestinal peptide (VIP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), two neuromodulator peptides in the glucagon superfamily, have demonstrated positive regulation of osteoblast proliferation and activity. Using acidic oligopeptides, we have developed ligands that target to and accumulate at fracture sites. These targeting ligands can be synthesized in sequence with bone anabolic peptides to minimize off target effects and increase potency at the fracture site to create safer and more efficacious therapeutic molecules. The conjugation of PACAP and VIP to acidic oligopeptide targeting ligands results in compounds that demonstrate significant improvements in regeneration of bone at fracture site in vivo in terms of strength and mineralization of fracture callus.
Session Track
Biotechnology and Chemistry
Recommended Citation
Nicholas A. Young, Jeffery J. Nielsen, and Philip S. Low,
"Targeting Neuropeptides to Bone Fractures for Accelerated Healing"
(August 2, 2018).
The Summer Undergraduate Research Fellowship (SURF) Symposium.
Paper 24.
https://docs.lib.purdue.edu/surf/2018/Presentations/24
Included in
Amino Acids, Peptides, and Proteins Commons, Animal Experimentation and Research Commons, Biotechnology Commons, Endocrinology Commons, Medicinal and Pharmaceutical Chemistry Commons
Targeting Neuropeptides to Bone Fractures for Accelerated Healing
In patients over the age of 65 especially, bone fractures represent a significant disease burden. Non-invasive drug therapies are not available for bone fractures which represents a problem for this population. Vasoactive intestinal peptide (VIP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP), two neuromodulator peptides in the glucagon superfamily, have demonstrated positive regulation of osteoblast proliferation and activity. Using acidic oligopeptides, we have developed ligands that target to and accumulate at fracture sites. These targeting ligands can be synthesized in sequence with bone anabolic peptides to minimize off target effects and increase potency at the fracture site to create safer and more efficacious therapeutic molecules. The conjugation of PACAP and VIP to acidic oligopeptide targeting ligands results in compounds that demonstrate significant improvements in regeneration of bone at fracture site in vivo in terms of strength and mineralization of fracture callus.
https://docs.lib.purdue.edu/surf/2018/Presentations/24